Atossa Therapeutics, INC 8-K filings

Atossa Therapeutics reports positive topline data from its Phase 2 KARISMA-Endoxifen study, showing significant reduction in mammographic breast density in premenopausal women.

Atossa Therapeutics announced its second quarter 2024 financial results, showcasing clinical advancements and a solid cash balance of $79.5 million.

Atossa Therapeutics' annual meeting saw stockholders approve an increase in authorized shares and an amendment to the 2020 Stock Incentive Plan, while the company appointed a new Chief Financial Officer.

Atossa Therapeutics announced first quarter 2024 financial results, highlighted by a 100% disease control rate in the EVANGELINE study and a strong cash balance of $84 million.

Atossa Therapeutics announced its year-end 2023 financial results, highlighted by $88.5 million in cash and the full enrollment of two Phase 2 clinical trials, with data expected in the second half of 2024.

Atossa Therapeutics reported its year-end 2023 financial results, highlighted clinical trial progress, and provided a corporate update, including the full enrollment of two Phase 2 studies and the first patient dosed in a new Phase 2 breast cancer prevention study.

Atossa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Atossa Therapeutics has appointed Dr. Tessa Cigler, a breast cancer specialist, to its Board of Directors to leverage her clinical trial and patient care experience.